Search company, investor...
Pulmatrix company logo

Pulmatrix

pulmatrix.com

Founded Year

2003

Stage

Reverse Merger | IPO

Total Raised

$69.88M

Market Cap

0.01B

Stock Price

3.62

About Pulmatrix

Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.

Headquarters Location

99 Hayden Avenue Suite 390

Lexington, Massachusetts, 02421,

United States

781-357-2333

Missing: Pulmatrix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pulmatrix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Pulmatrix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pulmatrix is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Pulmatrix Patents

Pulmatrix has filed 1 patent.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Muscarinic antagonists
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/15/2020

2/1/2022

Dosage forms, Drug delivery devices, Glucocorticoids, Muscarinic antagonists, Pregnanes

Grant

Application Date

9/15/2020

Grant Date

2/1/2022

Title

Related Topics

Dosage forms, Drug delivery devices, Glucocorticoids, Muscarinic antagonists, Pregnanes

Status

Grant

Latest Pulmatrix News

Axonics, Outset lead medtech space on Deloitte’s list of fastest growing companies

Nov 17, 2022

MassDevice Search this website Axonics, Outset lead medtech space on Deloitte’s list of fastest growing companies November 16, 2022 Deloitte today released its “ North America Technology Fast 500 ” list of growing companies, including a handful of medtech firms. The list, which ranking of the fastest-growing North American companies across a range of sectors, included several “Life Sciences” outfits. Immunology company Vir Biotechnology led the way in first place on the list. Axonics (Nasdaq:AXNX) represented the highest-ranked medical device company at No. 4. According to Deloitte, the company registered 25,401% growth over a three-year period. Axonics reported $180.3 million in revenue in fiscal 2021, compared to $707,000 in fiscal 2018. The company topped last year’s version of the list. Axonics develops novel products for adults with bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy-to-use, safe, clinically effective therapy. The company also markets Bulkamid, a urethral bulking hydrogel. “Axonics is proud to be recognized as one of the fastest-growing companies in North America,” Axonics CEO Raymond W. Cohen said in a news release. “The strong growth of Axonics is a testament to the mission-driven culture of the company, the dedication of our employees, and our commitment to continuous innovation. We have built a company that values diversity, quality, integrity, and teamwork. We remain focused on increasing awareness for Axonics’ best-in-class incontinence solutions, which have the potential to significantly improve the quality of life for millions of adults with bladder and bowel dysfunction.” Outset Medical makes the list Outset Medical (Nasdaq:OM) placed No. 33 on the Deloitte list. It recorded 5,012% growth over the three-year period. Outset brought in $103 million in revenues last year. San Jose, California-based Outset develops the Tablo hemodialysis system for kidney patients. The FDA-cleared connected and intelligent device offers two-way communication with the cloud. This allows for the sending of treatment data electronically. Physicians can remotely monitor patients so they feel connected to the medical team while comfortably remaining at home. The first-of-its-kind technology aims to reduce the cost and complexity of dialysis. Outset Chair and CEO Leslie Trigg said continued Tablo adoption in the acute and home markets drew its 2021 revenue growth. “Dialysis is a huge expense and burden on patients and providers,” said Trigg. “Tablo represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. We are honored to be recognized for our growth and share this award with all of our employees, partners, patients, physicians and families who are on the journey with us to improve the lives of kidney patients everywhere.” Pulmatrix nears the top 50 Lexington, Massachusetts-based Pulmatrix (Nasdaq:PULM) placed at No. 51 on the list. It registered growth of 3,278% from 2018 to 2021. Pulmatrix develops the patented iSperse technology. It designed iSperse to improve therapeutic delivery to the lungs. It maximizes local concentrations and reduces systemic side effects to improve patient outcomes. One indication Pulmatrix is pursuing is an orally inhaled migraine treatment. Others in the Deloitte Fast 500 Sight Sciences: 550% growth Inspire Medical Systems: 361% growth Inspire Medical Systems develops sleep apnea treatment technology. Tandem Diabetes Care: 282% growth Tandem Diabetes Care develops automated insulin delivery technology for people with diabetes. Fourteen medical devices ranging from patient monitoring to surgical robotics recently made it into Time magazine’s Best Inventions of 2022. For over 20 years, Time magazine has highlighted the 100 most impactful devices and ideas around the world. The list is compiled through nominations from the publication’s editors and global correspondents, with special attention to… […] Affera started in 2014 with a simple goal that paid off when Medtronic (NYSE:MDT) bought the company for up to $1 billion this year. Achieving that goal, however, took some unconventional and sometimes difficult design choices, Affera founder and CEO Doron Harlev said. Newton, Massachusetts–based Affera’s system diagnoses, maps and treats heart arrhythmias with ablation.… […] Viant today said it has completed the expansion of its Design & Development West Center of Excellence in Fremont, California. The facility’s footprint is now 67% larger, totaling 25,000 sf² across two buildings co-located with the company’s complex molding and assembly facility. The expansion triples the amount of ISO 8 and ISO 7 cleanroom space… […] Tecomet announced that it entered into a strategic partnership with additive manufacturer Precision ADM. Woburn, Massachusetts-based Tecomet’s partnership with Canada-based Precision ADM expands development and production opportunities. It will address both areas of additive and subtractive manufacturing. Specifically, Tecomet said in a news release that it focuses on the growth of additive manufacturing across medical… […] Schivo announced last week that it acquired APN Global and its APN Inc. operating subsidiary for an undisclosed amount. Waterford, Ireland-based Schivo said in a news release that the acquisition further solidifies its presence in North America. It also allows APN to continue growing in Quebec. The company will become the Schivo Group’s manufacturing center… […] Could robotics-led injection molding support manufacturing of the estimated 2 million different kinds of medical devices on the market? Nigel Smith, TM Robotics The COVID-19 pandemic led to a surge in demand for medical devices across hospitals and medical laboratories, and business analyst Mercer Capital predicts this growth will continue. Its Five Trends to Watch… […] Researchers at the University of Connecticut recently shared their development of a new method for charging brain stimulators. A report in Cell Reports Physical Sciences last month highlighted a charging method using a person’s own breathing movements. This could alleviate the issues caused by the surgery required each time an implantable deep brain stimluator’s batteries need changing.… […] A Stanford Medicine study observed the apparent curing of diabetes in mice following transplantation of insulin-secreting pancreatic islet cells. Researchers say the animals’ immune systems accepted the donated cells prior to transplantation. This occurs through a three-pronged process they say they could easily replicate in humans. The mice did not need immune-suppressing treatments after the… […] Donatelle (New Brighton, Minnesota) recently announced the opening of a new 2,600-square-foot ISO 7 clean room. The new space expands the contract manufacturer’s clean room facilities for Class I, Class II and Class III medical devices. In addition, it extends its high-volume production capabilities to support tens of millions more components per year. The clean… […] 3D printer accessibility and affordability are enabling small device firms to develop and market a wave of personalized devices. Gaurav Manchanda, Formlabs Healthcare is becoming more efficient, and patients are beginning to expect a personalized approach. 3D printing isn’t a newly minted manufacturing technology, yet it’s reached an inflection point for bringing change in healthcare… […]

Pulmatrix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pulmatrix Rank

Pulmatrix Frequently Asked Questions (FAQ)

  • When was Pulmatrix founded?

    Pulmatrix was founded in 2003.

  • Where is Pulmatrix's headquarters?

    Pulmatrix's headquarters is located at 99 Hayden Avenue, Lexington.

  • What is Pulmatrix's latest funding round?

    Pulmatrix's latest funding round is Reverse Merger.

  • How much did Pulmatrix raise?

    Pulmatrix raised a total of $69.88M.

  • Who are the investors of Pulmatrix?

    Investors of Pulmatrix include Ruthigen, Polaris Partners, 5AM Ventures, ARCH Venture Partners, Novartis Venture Funds and 6 more.

  • Who are Pulmatrix's competitors?

    Competitors of Pulmatrix include Arena Pharmaceuticals, Intarcia Therapeutics, Altor BioScience, Diffusion Pharmaceuticals, Elixir Pharmaceuticals and 11 more.

Compare Pulmatrix to Competitors

T
Terapio

Terapio is a biopharmaceutical company specializing in the development of a pipeline of therapies based on the transport protein, RLIP76.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

P
PDC Biotech

PDC Biotech is developing a compound, PDC31 which is being developed for the treatment of preterm labor and primary dysmenorrhea. PDC31 is a peptide antagonist of the prostaglandin F2a (FP) receptor, the lead in a series of FP antagonists exclusively licensed to PDC Biotech GmbH from Theratechnologies, (TSX: TH), a Canadian biopharmaceutical company.

Y
Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

O
Osteologix

Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.